Efficacy, safety, and immunological effects of a 2‐year immunotherapy with Depigoid® birch pollen extract: a randomized, double‐blind, placebo‐controlled study

Höiby, A.‐S.; Strand, Vibeke; Robinson, Douglas S.; Sager, Angelika; Rak, S.

doi:10.1111/j.1365-2222.2010.03521.x

Cited by 42 publications

(56 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In agreement with reviously published randomized, double-blind, placebo-controlled trials utilizing depigmented GA-modified pollen extracts,3,4 allergic symptoms of patients included in this open, uncontrolled, longitudinal study improved within the first year of allergoid-IT and remained decreased over the 3-year observation period (mean clinical improvement compared with baseline [m-6]: 31.5% [m6], 26.4% [m18] and 44.1% [m30];…”

supporting

confidence: 71%

See 1 more Smart Citation

Birch pollen allergen‐specific immunotherapy with glutaraldehyde‐modified allergoid induces IL‐10 secretion and protective antibody responses

Rauber

Adams

et al. 2019

Allergy

View full text Add to dashboard Cite

show abstract

supporting

confidence: 71%

“…While AIT with allergoids is clinically effective, 3,4 its immunological mechanisms leading to allergen tolerance are poorly characterized. Here, we followed 14 birch pollen (BP)-allergic patients treated with depigmented GA-modified BP extract (BPE) for up to 3 years analyzing allergen-specific humoral and T cellular immune parameters ( Figure S1).…”

mentioning

confidence: 99%

Birch pollen allergen‐specific immunotherapy with glutaraldehyde‐modified allergoid induces IL‐10 secretion and protective antibody responses

Rauber

Adams

et al. 2019

Allergy

View full text Add to dashboard Cite

show abstract

“…In order to further develop the methods for one and only one final endpoint for trials on SIT, new methods to establish a clinical relevant score evaluating the potential reduction in allergic symptoms in combination with the potential reduced need for symptomatic medication have been assessed [51,68,69]. Recently, the first validation of a combined symptom/medication score strategy was published as the "Allergy-Control-SCORE™".…”

Section: Introductionmentioning

confidence: 99%

“…A six-month treatment period with recombinant grass pollen major allergens has also proved effective [81]. A combined symptom/medication score strategy has recently been used and confirmed the clinical efficacy for short term injection therapy [51,68], as well as for sublingual tablet treatment [66]. …”

Section: Introductionmentioning

confidence: 99%

Allergen‐specific immunotherapy provides immediate, long‐term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit ‐the centenary of allergen specific subcutaneous immunotherapy

Jacobsen

Wahn

Bilò³

2012

Clinical & Translational All

View full text Add to dashboard Cite

Allergen Specific Immunotherapy (SIT) for respiratory allergic diseases is able to significantly improve symptoms as well as reduce the need for symptomatic medication, but SIT also has the capacity for long-term clinical effects and plays a protective role against the development of further allergies and symptoms. The treatment acts on basic immunological mechanisms, and has the potential to change the pathological allergic immune response. In this paper we discuss some of the most important achievements in the documentation of the benefits of immunotherapy, over the last 2 decades, which have marked a period of extensive research on the clinical effects and immunological background of the mechanisms involved. The outcome of immunotherapy is described as different levels of benefit from early reduction in symptoms over progressive clinical effects during treatment to long-term effects after discontinuation of the treatment and prevention of asthma. The efficacy of SIT increases the longer it is continued and immunological changes lead to potential long-term benefits. SIT alone and not the symptomatic treatment nor other avoidance measures has so far been documented as the therapy with long-term or preventive potential. The allergic condition is driven by a subset of T-helper lymphocytes (Th2), which are characterised by the production of cytokines like IL-4, and IL-5. Immunological changes following SIT lead to potential curative effects. One mechanism whereby immunotherapy suppresses the allergic response is through increased production of IgG4 antibodies. Induction of specific IgG4 is able to influence the allergic response in different ways and is related to immunological effector mechanisms, also responsible for the reduced late phase hyperreactivity and ongoing allergic inflammation. SIT is the only treatment which interferes with the basic pathophysiological mechanisms of the allergic disease, thereby creating the potential for changes in the long-term prognosis of respiratory allergy. SIT should not only be recognised as first-line therapeutic treatment for allergic rhinoconjunctivitis but also as secondary preventive treatment for respiratory allergic diseases.

show abstract

“…mast cells, eosinophils and neutrophils) [17], thereby preventing the release of cellular mediators and late-phase inflammation. Immunotherapy has been shown to be effective for allergies caused by Hymenoptera [18,19], some pollens [20], grasses [21], trees [22] and house dust mites [23]. However, data in the literature are relatively scarce on vaccine efficacy for allergic morbidity, especially asthma, caused by the American CR (ACR; Periplaneta americana ), which is the predominant CR species in Thailand and many other tropical countries.…”

Section: Introductionmentioning

confidence: 99%

Intranasal, Liposome-Adjuvanted Cockroach Allergy Vaccines Made of Refined Major Allergen and Whole-Body Extract of Periplaneta americana

Meechan¹,

Tungtrongchitr

Chaisri

et al. 2013

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Cockroach (CR) allergens frequently cause severe asthma in CR-sensitized subjects. Allergen-specific immunotherapy causes a shift of allergic Th2 responses towards Th1 and/or regulatory T cell (Treg) responses which reduce airway inflammation and prevent disease progression. Data are relatively limited on immunotherapy via CR allergy vaccine. Methods: The therapeutic efficacy of an intranasal liposome-adjuvant vaccine made of a refined Periplaneta americana arginine kinase (AK) was compared to the liposome-entrapped P. americana crude extract (CRE) vaccine. Adult BALB/c mice were rendered allergic to CRE. Three allergic mouse groups were immunized intranasally on alternate days with 8 doses of liposome-entrapped CRE (L-CRE), liposome-entrapped AK and placebo, respectively. One week later, all mice received a nebulized CRE provocation. Evaluation of vaccine efficacy was performed 1 day after provocation. Results: Liposome-entrapped native AK attenuated airway inflammation after the CRE provocation and caused a shift of allergic Th2 to Th1 and Treg responses. The L-CRE also induced a shift from the Th2 to the Th1 response but did not induce a Treg response and could not attenuate the airway inflammation upon allergen reexposure. Conclusions: Intranasal liposome-adjuvant CR allergy vaccine containing native AK (Per a 9) is better than L-CRE in attenuating allergic airway inflammation. The findings of this study not only document a more comprehensive and beneficial immune response induced by the refined allergen vaccine but also raise the point that the shift from the Th2 to the Th1 response alone might not correlate with improved airway histopathology, clinical outcome and quality of life.

show abstract

Efficacy, safety, and immunological effects of a 2‐year immunotherapy with Depigoid^® birch pollen extract: a randomized, double‐blind, placebo‐controlled study

Abstract: SCIT with depigmented polymerized birch pollen extract significantly reduced symptom and medication scores when compared with the placebo, was well tolerated, and resulted in immunological changes comparable with those of native pollen extracts.

Cited by 42 publications

References 38 publications

Birch pollen allergen‐specific immunotherapy with glutaraldehyde‐modified allergoid induces IL‐10 secretion and protective antibody responses

Birch pollen allergen‐specific immunotherapy with glutaraldehyde‐modified allergoid induces IL‐10 secretion and protective antibody responses

Allergen‐specific immunotherapy provides immediate, long‐term and preventive clinical effects in children and adults: the effects of immunotherapy can be categorised by level of benefit ‐the centenary of allergen specific subcutaneous immunotherapy

Intranasal, Liposome-Adjuvanted Cockroach Allergy Vaccines Made of Refined Major Allergen and Whole-Body Extract of <b><i>Periplaneta americana</i></b>

Contact Info

Product

Resources

About